New CRISPR advance may solve key quandary

A mutation unique to certain cancer tumors is a potential homing beacon for safely deploying CRISPR gene editing enzymes to disarm DNA that makes cancer cells resistant to treatment, while ignoring the gene in normal cells where it’s critical to healthy function, according to to a new study from ChristianaCare’s Gene Editing Institute in the journal Molecular Cancer Research.